Moreau et al developed a score for identifying a patient with multiple myeloma who is likely to have early progression-related death. The authors are from multiple institutions in Europe.
Patient selection: multiple myeloma treated with first-line autologous stem-cell transplantation
Outcome: death within 2 years of treatment initiation (early progression-related death)
Parameters:
(1) International Staging System (see 28.05.12)
(2) serum lactate dehydrogenase (LDH)
(3) cytogenetics
|
Parameter |
Finding |
Points |
|
International Staging System |
Stage 1 or 2 |
0 |
|
|
Stage 3 |
1 |
|
serum LDH |
normal |
0 |
|
|
above the upper limit of normal |
1 |
|
cytogenetics |
t(4;14) |
1 |
|
|
del(17p) |
1 |
|
|
neither |
0 |
total score =
= SUM(points for all 3 parameters)
Interpretation:
• minimum score: 0
• maximum score: 3
• The higher the score the greater the risk of early progression-related death.
|
Score |
2-Year Survival from Treatment Start |
|
0 |
93% |
|
1 |
86% |
|
2 |
73% |
|
3 |
52% |
Specialty: Hematology Oncology
ICD-10: ,
